Cardiol Therapeutics Inc
TSX:CRDL

Watchlist Manager
Cardiol Therapeutics Inc Logo
Cardiol Therapeutics Inc
TSX:CRDL
Watchlist
Price: 1.8 CAD -3.74% Market Closed
Market Cap: 146.9m CAD
Have any thoughts about
Cardiol Therapeutics Inc?
Write Note

Cardiol Therapeutics Inc
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Cardiol Therapeutics Inc
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Cardiol Therapeutics Inc
TSX:CRDL
Total Equity
CA$10.4m
CAGR 3-Years
-29%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
Canopy Growth Corp
TSX:WEED
Total Equity
CA$509.7m
CAGR 3-Years
-51%
CAGR 5-Years
-38%
CAGR 10-Years
36%
Sundial Growers Inc
NASDAQ:SNDL
Total Equity
CA$1.2B
CAGR 3-Years
66%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cronos Group Inc
TSX:CRON
Total Equity
$1.1B
CAGR 3-Years
-10%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
Total Equity
$262.2m
CAGR 3-Years
16%
CAGR 5-Years
150%
CAGR 10-Years
91%
C
Curaleaf Holdings Inc
CNSX:CURA
Total Equity
$1.1B
CAGR 3-Years
-8%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Cardiol Therapeutics Inc
Glance View

Market Cap
146.9m CAD
Industry
Pharmaceuticals

Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory therapies for cardiovascular disease (CVD). The company is headquartered in Oakville, Ontario and currently employs 11 full-time employees. The company went IPO on 2018-12-20. The firm's lead product, CardiolRx, is a pharmaceutically produced oral cannabidiol formulation that is in a Phase II/III study in hospitalized patients testing positive for COVID-19 with a prior history of, or risk factors for, cardiovascular disease. Cardiol has also received clearance from the Food and Drug Administration (FDA) for its investigational new drug (IND) application for a Phase II international trial that investigates the anti-inflammatory and anti- fibrotic properties of CardiolRx in patients with acute myocarditis, which is a common cause of sudden cardiac death in people under 35 years of age. In addition, Cardiol is developing a subcutaneous formulation of CardiolRx and other anti-inflammatory therapies for the treatment of chronic heart failure.

CRDL Intrinsic Value
0.73 CAD
Overvaluation 60%
Intrinsic Value
Price

See Also

What is Cardiol Therapeutics Inc's Total Equity?
Total Equity
10.4m CAD

Based on the financial report for Sep 30, 2024, Cardiol Therapeutics Inc's Total Equity amounts to 10.4m CAD.

What is Cardiol Therapeutics Inc's Total Equity growth rate?
Total Equity CAGR 5Y
-9%

Over the last year, the Total Equity growth was -70%. The average annual Total Equity growth rates for Cardiol Therapeutics Inc have been -29% over the past three years , -9% over the past five years .

Back to Top